Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4′-fluorouridine
Authors:
Preprint
Abstract
RNA viruses present a constant threat to human health, often with limited options for vaccination or therapy. Notable examples include influenza viruses and coronaviruses, which have pandemic potential. Filo- and henipaviruses cause more limited outbreaks, but with high case fatality rates. All RNA viruses rely on the activity of a virus-encoded RNA-dependent RNA polymerase (RdRp). An antiviral nucleoside analogue, 4′-Fluorouridine (4′-FlU), targets RdRp and diminishes the replication of several RNA viruses, including influenza A virus and SARS-CoV-2, through incorporation into nascent viral RNA and delayed chain termination. However, the effective concentration of 4′-FlU varied among different viruses, raising the need to fortify its efficacy. Here we show that inhibitors of dihydroorotate dehydrogenase (DHODH), an enzyme essential for pyrimidine biosynthesis, can synergistically enhance the antiviral effect of 4′-FlU against influenza A viruses, SARS-CoV-2, henipaviruses, and Ebola virus. Even 4′-FlU-resistant mutant influenza A virus was re-sensitized towards 4′-FlU by DHODH inhibition. The addition of uridine rescued influenza A virus replication, strongly suggesting uridine depletion as a mechanism of this synergy. 4′-FlU was also highly effective against SARS-CoV-2 in a hamster model of COVID. We propose that the impairment of endogenous uridine synthesis by DHODH inhibition enhances the incorporation of 4′-FlU into viral RNAs. This strategy may be broadly applicable to enhance the efficacy of pyrimidine nucleoside analogues for antiviral therapy. Graphical HIGHLIGHTS: Strong synergy of DHODH inhibitors with 4′-FlU Activity of the combination against previously resistant influenza virus Broadly active combination against a diverse set of RNA viruses Successful targets include highly pathogenic Ebola and Nipah virusesKeywords
All Related Versions
- Published version: Antiviral Research, 233, 106046.
This publication has 74 references indexed in Scilit:
- Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological ApproachesInfectious Diseases and Therapy, 2024
- Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virusJournal of Medical Virology, 2024
- Dexamethasone for Inpatients With COVID-19 in a National CohortJAMA Network Open, 2023
- The synergy between nucleotide biosynthesis inhibitors and antiviral nucleosides: New opportunities against viral infections?Archiv der Pharmazie, 2022
- Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2Protein & Cell, 2020
- Susceptibility of paramyxoviruses and filoviruses to inhibition by 2′-monofluoro- and 2′-difluoro-4′-azidocytidine analogsAntiviral Research, 2018
- Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomideBiochemical Pharmacology, 1995
- Infectious rabies viruses from cloned cDNA.The EMBO Journal, 1994
- Efficient selection for high-expression transfectants with a novel eukaryotic vectorGene, 1991
- Beitrag zur kollektiven Behandlung pharmakologischer ReihenversucheNaunyn-Schmiedeberg's Archives of Pharmacology, 1931